Table VI.
Molecular subtypes and the number of metastatic sites in patients with metastatic breast cancer from the present cohort study (n=166).
| Number of metastatic sites | HR+/HER2− (n=92) | HR+/HER2+ (n=26) | HR-/HER2+ (n=21) | HR-/HER2- (n=27) | χ2 | P-value |
|---|---|---|---|---|---|---|
| 1 | 55 (59.8) | 12 (46.2) | 12 (57.1) | 13 (48.2) | 11.328 | 0.221 |
| 2 | 20 (21.7) | 8 (30.8) | 4 (19.1) | 10 (37.0) | ||
| 3 | 10 (10.9) | 5 (19.2) | 2 (9.5) | 0 (0) | ||
| ≥4 | 7 (7.6) | 1 (3.8) | 3 (14.3) | 4 (14.8) |
Values are expressed as n (%). HR, hormone receptor; HER2, human epidermal growth factor receptor 2. P-value pertains to comparison among all groups.